Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis

NCT03633708 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03633708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03633708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Recruiting
Start date
April 29, 2019
Completion date
January 31, 2029
Enrollment
56 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, secondary hyperparathyroidism